Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 15/20 | 0.67 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.66 |
| ▸ | NSD2 | O96028 | 1/20 | 0.66 |
| ▸ | NQO1 | P15559 | 2/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132250 | 0.95 | NQO2 (0.67) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL14291793 | 0.91 | NQO2 (0.69) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526702 | 0.86 | NQO2 (0.70) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526651 | 0.85 | NQO2 (0.69) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526710 | 0.85 | NQO2 (0.70) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526629 | 0.84 | NQO2 (0.67) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526632 | 0.83 | NQO2 (0.69) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526639 | 0.83 | NQO2 (0.66) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL7220854 | 0.80 | NQO2 (0.71) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526642 | 0.80 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| WO-2008016661-A2 | MORPHOLINO COMPOUNDS FOR TREATING INFLAMMATORY AND DEMYELINATING DISEASES AND CANCERS | XANTHUS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | FLT3, CSF3R, ABL1 | NQO2 616/4885SMARCA2 1943/4885NSD2 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.